# Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases

> **NCT05794971** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 126 (estimated)

## Conditions studied

- Colorectal Cancer Liver Metastases
- Regorafenib

## Interventions

- **DRUG:** Regorafenib and DIBIRI
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT05794971
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-10
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05794971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05794971, "Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05794971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*